Journal article

Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multicenter study

Alexander C Leeksma, Panagiotis Baliakas, Theodoros Moysiadis, Anna Puiggros, Karla Plevova, Anne-Marie van der Kevie-Kersemaekers, Hidde Posthuma, Ana E Rodriguez-Vicente, Anh Nhi Tran, Gisela Barbany, Larry Mansouri, Rebeqa Gunnarsson, Helen Parker, Eva van den Berg, Mar Bellido, Zadie Davis, Meaghan Wall, Ilaria Scarpelli, Anders Osterborg, Lotta Hansson Show all

Haematologica: the hematology journal | FERRATA STORTI FOUNDATION | Published : 2021

Abstract

Complex karyotype (CK) identified by chromosome-banding analysis (CBA) has shown prognostic value in chronic lymphocytic leukemia (CLL). Genomic arrays offer high-resolution genome-wide detection of copy-number alterations (CNAs) and could therefore be well equipped to detect the presence of a CK. Current knowledge on genomic arrays in CLL is based on outcomes of single center studies, in which different cutoffs for CNA calling were used. To further determine the clinical utility of genomic arrays for CNA assessment in CLL diagnostics, we retrospectively analyzed 2293 arrays from 13 diagnostic laboratories according to established standards. CNAs were found outside regions captured by CLL FI..

View full abstract

Grants

Awarded by Bloodwise


Awarded by Kay Kendall Leukaemia Fund


Awarded by Cancer Research UK


Awarded by project MHCR DRO


Awarded by research infrastructure NCMG


Awarded by research infrastructure EATRIS-CZ


Awarded by MEYS CR


Funding Acknowledgements

The authors gratefully acknowledge all patients who contributed to this study. This study was partly funded by an unrestricted contribution from Janssen Pharmaceuticals and from GILEAD Sciences SA. The funding sources had no role in identifying statements, abstracting data, synthesizing results, grading evidence or preparing the manuscript, or in the decision to submit the manuscript for publication. ACL is supported by the Peters van der Laan foundation. JCS was funded by Bloodwise (11052, 12036), the Kay Kendall Leukaemia Fund (873), Cancer Research UK (C34999/A18087, ECMC C24563/A15581), Wessex Medical Research and the Bournemouth Leukaemia Fund. KP, MJ, and SP are supported by the project MHCR DRO n. 65269705, the research infrastructures NCMG LM2015091, and EATRIS-CZ LM2015064, and the project CEITEC2020 LQ1601, funded by MEYS CR. RR is supported by the Swedish Cancer Society, the Swedish Research Council, the Knut and Alice Wallenberg Foundation, Karolinska Institutet, Karolinska University Hospital, and Radiumhemmets Forskningsfonder, Stockholm.